(Total Views: 625)
Posted On: 07/03/2025 6:57:19 PM
Post# of 156147

AstraZeneca contemplating a $15B licensing deal for Summit's Keytruda killer, ivonescimab. Hmmm.... makes you wonder how much Merck would pay us so they can combine leronlimab with Keytruda and fight off ivonescimab.
https://pharmaphorum.com/news/summit-climbs-r...a-interest
https://pharmaphorum.com/news/summit-climbs-r...a-interest

